Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
  • Clinical practice guidelines for Chagas disease: Recent developments and future needs
  • Novel oxaborole, nitroimidazole, and aminopyrazoles with activity against experimental cutaneous leishmaniasis

RSS PRESS RELEASES

  • DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases
  • Chagas disease: the time is now to end 110 years of neglect
  • GARDP set up as independent legal entity

RSS NEWS

  • DNDi uses global mobile data service developed by FIND to manage clinical data in the Democratic Republic of Congo
  • 2018 highlights from DNDi offices around the world
  • DNDi remembers Derrick Wong, highly valued Board member

RSS IN THE MEDIA

  • BioSpace: “BioSpace’ s Global Biopharma Roundup”
  • BioCentury: “Atomwise unveils Chagas disease compounds from AIMS program”
  • El Dia: “Reducir dosis y duración de tratamiento del Chagas es tan eficaz y más seguro”

RSS EVENTS

  • 2nd LEAP Scientific Conference
  • European Conferences on Biomedical Optics
  • Wellcome Centre for Anti-Infective Research at the University of Dundee

RSS Scientific Articles

  • A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole
  • Clinical practice guidelines for Chagas disease: Recent developments and future needs
  • Novel oxaborole, nitroimidazole, and aminopyrazoles with activity against experimental cutaneous leishmaniasis
  • Cutaneous leishmaniasis and co-morbid major depressive disorder: A systematic review with burden estimates

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website
  • GARDP

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

Social Mission Ration 2017

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close